Veterinary Renal Disease

Global Veterinary Renal Disease Market to Reach US$20.7 Billion by 2030

The global market for Veterinary Renal Disease estimated at US$16.0 Billion in the year 2024, is expected to reach US$20.7 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Diagnosis, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$14.0 Billion by the end of the analysis period. Growth in the Treatment segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 8.2% CAGR

The Veterinary Renal Disease market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Veterinary Renal Disease Market – Key Trends & Drivers Summarized

Why Is Veterinary Renal Disease Becoming a Major Concern in Animal Health?

Renal disease is becoming an increasingly prevalent health issue in companion animals, particularly among aging cats and dogs. Chronic kidney disease (CKD) is one of the most commonly diagnosed conditions in senior pets, leading to progressive loss of kidney function and severe health complications if left untreated. Factors such as poor diet, genetic predisposition, exposure to toxins, and underlying conditions like hypertension and diabetes contribute to the rising incidence of renal disease in animals. In addition to CKD, acute kidney injury (AKI) caused by infections, dehydration, or exposure to nephrotoxic substances is a significant concern in veterinary medicine. Livestock and equine populations are also susceptible to kidney disorders, often linked to dehydration, medication side effects, and metabolic imbalances. As veterinary care advances, early detection and improved treatment protocols for renal diseases are becoming priorities, with veterinarians focusing on dietary management, fluid therapy, and pharmacological interventions to slow disease progression and enhance the quality of life for affected animals. The growing awareness of renal health among pet owners has led to increased demand for specialized veterinary care, diagnostic screening, and therapeutic solutions, positioning the veterinary renal disease market for sustained growth.

What Are the Latest Advancements in the Diagnosis and Treatment of Veterinary Renal Disease?

Veterinary medicine has seen significant advancements in the diagnosis and management of renal disease, enabling earlier detection and more effective treatment strategies. One of the most impactful innovations is the use of biomarker-based blood and urine tests, which allow veterinarians to diagnose kidney disease before clinical symptoms become evident. These diagnostic tools, including symmetric dimethylarginine (SDMA) testing, have improved the accuracy of renal disease detection, facilitating timely interventions. Advanced imaging techniques such as ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) are also being increasingly utilized to assess kidney structure and detect abnormalities. In terms of treatment, therapeutic diets formulated with restricted protein, phosphorus, and sodium are now widely recommended for managing CKD in pets, significantly extending their lifespan. Additionally, pharmaceutical advancements have led to the development of renoprotective drugs, including angiotensin-converting enzyme (ACE) inhibitors, phosphate binders, and potassium supplements, which help slow disease progression. Emerging therapies such as stem cell treatment and regenerative medicine are showing promise in restoring kidney function and improving treatment outcomes. Fluid therapy and extracorporeal renal replacement therapy (RRT), including hemodialysis, are also becoming more common in specialized veterinary hospitals, offering critical care solutions for acute kidney injuries. These advancements are making renal disease more manageable and improving survival rates in affected animals.

What Challenges Are Hindering the Veterinary Renal Disease Market?

Despite advancements in veterinary nephrology, several challenges hinder the widespread adoption of renal disease treatments. One of the most significant obstacles is the difficulty of early diagnosis, as kidney disease often remains asymptomatic until it has reached an advanced stage. Many pet owners are unaware of the importance of routine kidney function testing, leading to delayed treatment and poor prognoses. Another challenge is the limited availability of advanced renal treatments, such as dialysis and renal transplants, which are offered only in a few specialized veterinary centers due to the high cost and technical complexity of these procedures. Compliance with long-term treatment regimens also poses difficulties, as pets with chronic kidney disease require lifelong dietary modifications, regular medication, and frequent veterinary visits, which can be financially burdensome for owners. Additionally, the lack of veterinary professionals specializing in nephrology limits access to expert care, particularly in developing regions. Addressing these challenges requires increased awareness campaigns about renal disease prevention, improved accessibility to diagnostic tools, and continued investment in research and development to create more effective and affordable treatment options.

What Are the Key Growth Drivers of the Veterinary Renal Disease Market?

The growth in the veterinary renal disease market is driven by several factors, including rising pet longevity, advancements in diagnostic testing, and increasing consumer demand for specialized veterinary care. With pets living longer due to improved healthcare, the prevalence of age-related diseases, including kidney disorders, has increased, necessitating better treatment solutions. The growing availability of advanced diagnostic tools, such as biomarker-based screening and imaging technologies, has enabled veterinarians to detect renal disease at earlier stages, improving treatment outcomes. The expansion of veterinary specialty hospitals and referral clinics has also contributed to market growth, providing pet owners with access to state-of-the-art renal care. Additionally, pet insurance companies are increasingly covering chronic disease management, encouraging more owners to seek early diagnosis and comprehensive treatment plans for their pets. The ongoing development of renoprotective drugs and novel therapies, such as regenerative medicine, is further propelling the market, offering new hope for pets with kidney disease. With continued research, increasing awareness, and technological advancements, the veterinary renal disease market is poised for sustained expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Veterinary Renal Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Diagnosis, Treatment); Animal Type (Canine, Feline, Bovine, Equine, Others); Administration Route (Oral, Injectable); Indication (Renal Failure, Chronic Kidney Disease, Renal Cystitis, Kidney Stones, Nephritis, Others); Distribution Channel (Veterinary Hospitals & Clinics, Pet Specialty Stores, E-Commerce, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Bayer Animal Health
• Boehringer Ingelheim Animal Health
• Ceva Santé Animale
• Dechra Pharmaceuticals
• Elanco Animal Health Incorporated
• FUJIFILM Holdings Corporation
• General Mills Inc.
• Hill`s Pet Nutrition
• IDEXX Laboratories, Inc.
• J.M. Smucker Company
• Mars Incorporated
• Merck & Co., Inc.
• Mission Pharmacal Company
• Nestlé Purina PetCare
• Neogen Corporation
• Phibro Animal Health Corporation
• Rayne Clinical Nutrition
• Richmond Vet Pharma
• Roquette Frères
• TriviumVet

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.